ClinicalTrials.gg

Program

BL0175

A development code. Also written as “BL0175 Injection”.

Its studies are mostly in Breast Neoplasms, led by Shanghai Best-Link Bioscience.

Furthest: phase 2, since Jun 12, 20263 company-led studies, 3 open or runningNext primary completion: Oct 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Best-Link Bioscience33 open or runningphase 2since Jun 12, 2026Dec 9, 2024Oct 31, 2027phase 2 · NCT07658183

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2024First study: phase 1 study in Breast NeoplasmsFirst studyNCT06738966 · 9 planned · China
  2. Jan 13, 2026Phase 1 study in Postmenopausal WomenNCT07366632 · 27 planned
  3. Jun 12, 2026Phase 2 study in Breast NeoplasmsPhase 2 reachedNCT07658183 · 120 planned · China

Ahead

  1. Oct 31, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT07658183

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07658183Breast Neoplasms · China2RecruitingOct 31, 2027120
NCT07366632Postmenopausal Women1Not yet recruitingMay 8, 202627
NCT06738966Breast Neoplasms · China1RecruitingFeb 20, 20269

How it is read

Names in the registry

  • “BL0175 Injection”, 2 entries
  • “BL0175”, 2 entries

Codes read as this program: BL0175.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.